

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	17/03/2020	17/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	01/04/2020		15												
20/WS/0070	275797	FINEARTS-HF (Finerenone trial in patients with Heart Failure)	06/11/2019	11/08/2020	04/06/2020	06/10/2020	06/10/2020	08/10/2020	19/10/2020		69												
19/NW/0712	272690	PACIFIC-AF Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation	18/09/2019	02/09/2020	31/01/2020	27/10/2020	27/10/2020	10/11/2020	27/11/2020		86				Y							Site staff prioritised UPH Covid-19 studies	NHS Provider
19/NW/0462	251756	Chronic Endometriosis and Recurrent Miscarriage - The CERM trial	14/02/2020	14/10/2020	20/08/2019	20/11/2020	20/11/2020	01/12/2020	30/12/2020		77				Y							Site staff prioritised UPH Covid-19 studies	NHS Provider
18/LO/2033	252294	WILL - When to Induce Labour to Limit risk in pregnancy hypertension	16/04/2019	12/10/2020	10/01/2019	20/11/2020	20/11/2020	01/12/2020	23/04/2021		193				Y							Site staff prioritised UPH Covid-19 studies	NHS Provider
19/LO/0951	248335	MITHRIDATE: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamide or interferon Alpha as first line Therapy for high risk polycythemia vera	20/02/2020	25/11/2020	16/08/2019	04/12/2020	15/01/2021	17/02/2021						Y								Site staff prioritised UPH Covid-19 studies	NHS Provider
20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).	22/09/2020	22/09/2020	25/09/2020	05/11/2020	23/11/2020	27/11/2020	17/12/2020		86			Y								Sponsor delays with set up including contracts, Sponsor delay in sending out kits, site were not allowed to issue C&C until kits received at site	Sponsor
20/SC/0350	285300	Acceptability of a ready to use, low calorie, low volume, high protein liquid for patients with increased protein needs	10/11/2020	04/12/2020	22/10/2020	11/12/2020	11/12/2020	11/12/2020	08/01/2021		35												

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability / issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
20/LO/1056	277635	Venetoclax o.r Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study	23/10/2020	14/12/2020	08/10/2020	12/04/2021	16/04/2021									Y						Site staff prioritised UPH Covid-19 studies	NHS Provider